May 14, 2018

Beam Therapeutics Launched to Develop Harvard Base Editing Technology toward Precision Genetic Medicines

Harvard innovations enable the correction of single-base mutations in DNA with unprecedented precision and efficiency

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Harvard University has granted a worldwide license to Beam Therapeutics, Inc., to develop and commercialize a suite of revolutionary DNA base editing technologies for the treatment of human disease.

The versatile platform of base editing technologies was invented by David R. Liu, PhD, Professor of Chemistry and Chemical Biology, and visionary postdoctoral fellows and graduate students in his Harvard laboratory.

“We developed programmable molecular machines that go to a target site of our choosing in the genomic DNA of a cell and directly convert one base to another base without making a double-stranded break in the DNA,” said Liu, who is a cofounder of Beam.

Read more

Back to News